腎細胞癌の疫学的予測

◆英語タイトル:EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
◆商品コード:GDHCER119-16
◆発行会社(調査会社):GlobalData
◆発行日:2016年6月1日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥443,445見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥886,890見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,330,335見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、腎細胞癌の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・腎細胞癌の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・腎細胞癌の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to 2023

Summary

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period. The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets.The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.

Scope

- The Renal cell carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.
- The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RCC EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global RCC market.
- Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RCC therapeutics in each of the markets covered.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Survival Rates for RCC – 8MM 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 20
3.4.3 Forecast Assumptions and Methods, RCC Diagnosed Incident Cases 21
3.4.4 Forecast Assumptions and Methods, RCC Five-Year Diagnosed Prevalent Cases 21
3.4.5 Forecast Assumptions and Methods, RCC Clinical Stages at Diagnosis 22
3.5 Epidemiological Forecast for RCC (2013-2023) 23
3.5.1 Diagnosed Incident Cases of RCC 23
3.5.2 Age-Specific Diagnosed Incident Cases of RCC 25
3.5.3 Sex-Specific Diagnosed Incident Cases of RCC 27
3.5.4 Age-Standardized Diagnosed Incidence of RCC 29
3.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 31
3.5.6 Five-Year Diagnosed Prevalent Cases of RCC 32
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 34
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 39
4.2.1 Epidemiologists 39
4.2.2 Reviewers 39
4.2.3 Global Director of Therapy Analysis and Epidemiology 40
4.2.4 Global Head of Healthcare 40
4.3 About GlobalData 41
4.4 About EpiCast 41
4.5 Disclaimer 42

1.1 List of Tables
Table 1: RCC Clinical Stages at Diagnosis 10
Table 2: Risk Factors and Comorbidities for RCC 11
Table 3: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007 12
Table 4: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007 13
Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007 13
Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007 14
Table 7: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2009 15
Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases 16
Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases 16
Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 17
Table 11: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 24
Table 12: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 26
Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013 28
Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 32

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 24
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 27
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013 29
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013 30
Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013 31
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 33

★調査レポート[腎細胞癌の疫学的予測]販売に関する免責事項
★調査レポート[腎細胞癌の疫学的予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆